Attenuation of sepsis-associated acute lung injury by lncRNA LINC00052 via sponging miR-106b-5p Authors: Kun Wang, Yanan Guo, Xianfeng Yu Published: 2026 ABSTRACT BackgroundSepsis-associated acute lung injury (SA-ALI) is a prevalent sequela of sepsis, which imposes a substantial public health burden. Due to the incomplete understanding of its underlying pathogenesis, no fundamental breakthroughs in its treatment have been achieved. To explore the predictive value of LINC00052 and miR-106b-5p in SA-ALI and clarify its mechanism.MethodsLINC00052 and miR-106b-5p levels were quantified using real-time quantitative polymerase chain reaction (RT-qPCR). The predictive capacity for SA-ALI was assessed using receiver operating characteristic (ROC) curve analysis. Risk factors associated with ALI development were evaluated by Logistic regression. Pearson analysis was conducted to examine the correlation between LINC00052 and clinical indicators. Cellular viability was determined via cell counting kit-8 (CCK-8) assay and flow cytometry, while the concentrations of inflammatory and apoptotic factors were measured using enzyme-linked immunosorbent assay (ELISA) and Western blotting (WB).ResultsLINC00052 levels in serum from sepsis patients were lower than in the healthy group and further decreased with the development of SA-ALI, whereas miR-106b-5p expression showed the opposite trend. LINC00052 and miR-106b-5p demonstrated high diagnostic value in distinguishing ALI patients, with enhanced predictive efficacy when combined. LINC00052 expression was inversely correlated with clinical indicators in SA-ALI patients. Mechanistically, upregulation of LINC00052 modulated proliferation, apoptosis, inflammation, and apoptosis markers in A549 cells, an effect cancelled by miR-106b-5p mimic.ConclusionsLINC00052 functions by sponging miR-106b-5p to suppress apoptosis and mitigate inflammation, with the LINC00052/miR-106b-5p axis exhibits excellent predictive value for SA-ALI, underscoring their clinical relevance as both therapeutic targets and diagnostic biomarkers. Background Sepsis is understood as a condition wherein a dysregulated host response to infection precipitates life-threatening organ dysfunction, often initiated by the invasion of pathogenic microorganisms or their toxins into the bloodstream [1, 2]. Clinically, it is characterized by signs such as fever, shock and tachycardia, and may even progress to multiple organ failure [3]. Among its most severe complications is sepsis-associated acute lung injury (SA-ALI), which is characterized by disruption of the alveolar capillary barrier and formation of pulmonary edema, leading to impaired gas exchange [4]. With roughly 14,000 individuals succumbing to sepsis and its complications every day, this condition poses a critical and ongoing challenge to human health on a global scale [5]. Although enhanced supportive treatments for sepsis, the mechanistic understanding of SA-ALI is still limited. Hence, further research into the biological underpinnings of sepsis is vital to improve early detection and refine clinical decision-making. Recent studies have highlighted the impact of non-coding RNAs, including lncRNAs and miRNAs, in modulating the progression of sepsis [6–8]. For example, lncRNA SNHG1 mediates DNMT1/Bcl-2 axis to aggravate myocardial injury caused by sepsis [9]. LncRNA CASC2 targets miR-152-3p to alleviate the progression of SA-ALI [10]. LncRNA LINC00052 (LINC00052) is encoded on human chromosome 15 and has been documented to be dysregulated across multiple pathological conditions [11]. LINC00052 has been reported to be markedly reduced in acute kidney injury patients and cellular models, and it improves patient outcomes by sponging miR-532-3p [12]. Furthermore, LINC00052 has been found to be downregulated in hyperoxia-induced lung injury in rats [13]. However, its function in SA-ALI remains poorly characterized. Emerging evidence suggests that lncRNAs regulating disease exacerbation by sponging miRNAs [14]. Among these miRNAs, miR-106b-5p was reported to participate in inflammatory signaling and apoptotic pathways [15, 16]. Interestingly, miR-106b-5p was revealed abnormally expressed in sepsis-associated cardiac dysfunction [17]. Given its established role in sepsis-related conditions, miR-106b-5p represents a promising candidate for further investigation in the context of SA-ALI. Therefore, we investigate the potential of LINC00052 and miR-106b-5p as early diagnostic biomarkers for SA-ALI. Furthermore, to elucidate the molecular mechanisms underlying SA-ALI, we established ALI cell models to reveal that LINC00052 regulates cellular activity and inflammatory responses by targeting miR-106b-5p. The findings are expected to provide novel insights into the pathological mechanisms of SA-ALI and offer theoretical and experimental basis for developing novel therapeutic targets for sepsis, while also providing new molecular clues for clinical care and risk monitoring of sepsis patients. Methods Basic clinical information of patients From August 2023 to December 2024, 170 patients admitted to Ganzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People’s Hospital) were classified as the sepsis group, and another 80 healthy individuals who underwent physical examinations during the same period were selected as the healthy group. Patients with sepsis were further grouped according to whether they had concurrent ALI. Among them, 82 cases were in the non-ALI group and 88 cases were in the ALI group. Inclusion criteria comprised adult patients who met the diagnostic criteria for both sepsis and ALI [18, 19], had complete clinical data available, received a standardized care protocol, and provided voluntary informed consent. Exclusion criteria included the presence of concurrent malignant tumors, coexisting severe complications such as respiratory failure, or cases of ALI attributed to non-sepsis etiologies. The trial protocol was reviewed and approved by the Institutional Ethics Committee of Ganzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People’s Hospital). Cell culture and model construction The human lung epithelial cell line A549 was sourced from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cell culture was performed using Dulbecco’s modified Eagle’s medium (DMEM) medium (Invitrogen, USA) enriched with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin. All cells were kept under standard conditions at 37 °C. A549 cells were exposed to 10 µg/mL lipopolysaccharide (LPS; Solarbio, China) for 24 h prior to mechanistic investigations of ALI. Transfection assay LINC00052 overexpression (ov-LINC00052) and miR-106b-5p mimic/inhibitor were synthesized by RiboBio. A549 cells were seeded into a 6-well plate at a density of 2 × 10⁵ cells/well and cultured overnight. Transfection of A549 cells was performed using lipofectamine 3000 reagent (Invitrogen, USA). RT-qPCR assay RNA was isolated using TRIzol reagent. For the synthesis of circular DNA (cDNA), the PrimeScript RT Kit (TaKaRa, Japan) was utilized for lncRNAs, whereas the PrimeScript miRNA cDNA Synthesis Kit (TaKaRa, Japan) was specifically employed for miRNAs. Subsequently, RT-qPCR was performed on 7500 Real-Time PCR System with SYBR® Premix Ex Taq™ (Takara Bio). The reaction conditions are as follows: 30 s of pre-denaturation at 95 °C, followed by 5 s of denaturation at 95 °C, and 30 s of annealing/extension at 60 °C, for a total of 40 cycles. β-actin and U6 served as the endogenous reference. The calculated via the 2−ΔΔCt method. To ensure the reliability of the results, the experiment was performed with three technical replicates, and each group included at least three biological replicates. The primer sequences are as follows: LINC00052, F-5’-CCTATCCCTTTCTCTAAGAA-3’, R-5’-ACTTCTGCAAAAACGTGCTG-3’; miR-106b-5p, F-5’-TGCGGCAACACCAGTCGATGG-3’, R-5’-CCAGTGC AGGGTCCGAGGT-3’; β-actin, F-5’-CACGAAACTACCTTCAACTCC-3’, R-5’-CATACTCCTGCTTGCTGATC-3’; U6, F-5’-GCTTCGGCAGCACATATACTAA-3’, R-5’-CGCTTCACGAATTTGCGTGT-3’. Cell proliferation and apoptosis assays A 100 µL of cell suspension containing 4 × 10³ cells/well was dispensed into 96-well plate and cultured for 48 h. Following this, each well received 10 µL of CCK-8 solution (Sigma-Aldrich, USA). After 3 h incubation period at 37 °C, the absorbance at 450 nm was quantified using a microplate spectrophotometer (Thermo Fisher Scientific, USA). A549 cells were detached using trypsin and resuspended 5 µL each of Annexin V-FITC and PI. After incubation at in the dark for 15 min, cell apoptosis was assessed. Luciferase report assay The LINC00052 sequence with the miR-106b-5p binding sites was cloned into the pmirGLO vector (Promega, Shanghai, China), and wild-type and mutant recombinant plasmids were constructed respectively, which named WT-LINC00052 and MUT-LINC00052. Subsequently, the cells were co-transfected with WT-LINC00052 or MUT-LINC00052, along with miR-106b-5p mimic or inhibitor, using lipofectamine 3000 reagent. After 48 h, luciferase activity was measured. ELISA assay Concentrations of the inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-1beta (IL-1β) in cell culture supernatants were quantified using an ELISA kit (Promega, Germany). Western blotting Total cellular proteins were extracted with RIPA buffer, quantified by BCA assay, and normalized to equal concentrations. After denaturation in loading buffer (98 °C, 5 min), proteins were separated by SDS-PAGE and electro-transferred onto PVDF membranes. Incubation with primary antibodies (4 °C, overnight), and subsequently with HRP-conjugated secondary antibodies (2 h). Protein expression levels were normalized to β-actin as an internal control. Statistical analysis Date was performed and analyzed using SPSS software (version 26.0) and GraphPad Prism (version 9.0). Comparisons between groups were conducted using the student’s t-test or one-way analysis of variance (ANOVA), with Tukey’s post hoc test. ROC curve analysis was employed to assess the predictive value of LINC00052 and miR-106b-5p in differentiating SA-ALI. Binary Logistic regression model was applied to identify the independent influencing factors associated with SA-ALI. P value of less than 0.05 was considered indicative of statistical significance. Results Baseline characteristics of subjects Table 1 summarizes the clinical characteristics of both septic patients and healthy volunteers. Statistically significant elevations in the concentrations of C-reactive protein (CRP), procalcitonin (PCT), cystatin C (CysC), and white blood cell count (WBC) were observed in the sepsis group compared to the healthy volunteer group (P < 0.001). Table 1Analysis of clinical data of the participantsIndicatorsHealthy group (n = 80)Sepsis group (n = 170)P valueGender (male/female)45/3598/720.836Age (years)55.16 ± 11.0357.30 ± 8.570.101BMI (kg/m2)25.25 ± 3.0224.78 ± 3.010.247CRP (mg/L)0.80 ± 0.2824.27 ± 4.34< 0.001PCT (ng/mL)0.52 ± 0.256.29 ± 1.98< 0.001CysC (mg/L)0.54 ± 0.171.33 ± 0.30< 0.001WBC (109/L)5.67 ± 1.9112.35 ± 4.76< 0.001APACHE II score-23.11 ± 5.32-SOFA score-11.14 ± 2.45-Hypertension (n/%)34/42.5056/32.940.143CHD (n/%)17/21.2544/25.880.428Diabetes (n/%)29/36.2575/44.120.241Abbreviation: BMI, body mass index; CRP, C-reactive protein; PCT, procalcitonin; CysC, Cystatin C; PLT, Platelet; WBC, white blood cells; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; CHD, Coronary heart disease Table 1Analysis of clinical data of the participantsIndicatorsHealthy group (n = 80)Sepsis group (n = 170)P valueGender (male/female)45/3598/720.836Age (years)55.16 ± 11.0357.30 ± 8.570.101BMI (kg/m2)25.25 ± 3.0224.78 ± 3.010.247CRP (mg/L)0.80 ± 0.2824.27 ± 4.34< 0.001PCT (ng/mL)0.52 ± 0.256.29 ± 1.98< 0.001CysC (mg/L)0.54 ± 0.171.33 ± 0.30< 0.001WBC (109/L)5.67 ± 1.9112.35 ± 4.76< 0.001APACHE II score-23.11 ± 5.32-SOFA score-11.14 ± 2.45-Hypertension (n/%)34/42.5056/32.940.143CHD (n/%)17/21.2544/25.880.428Diabetes (n/%)29/36.2575/44.120.241Abbreviation: BMI, body mass index; CRP, C-reactive protein; PCT, procalcitonin; CysC, Cystatin C; PLT, Platelet; WBC, white blood cells; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; CHD, Coronary heart disease Analysis of clinical data of the participants Abbreviation: BMI, body mass index; CRP, C-reactive protein; PCT, procalcitonin; CysC, Cystatin C; PLT, Platelet; WBC, white blood cells; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; CHD, Coronary heart disease Futhermore, the ALI group exhibited higher levels of CRP, PCT, CysC, and WBC compared to the non-ALI group. Similarly, both the APACHE II and SOFA scores were elevated in the ALI group, with all differences reaching statistical significance (P < 0.001, Table 2). Table 2Grouping and clinical data comparison of sepsis patientsIndicatorsSepsis group (n = 170)P valueNon-ALI (n = 82)ALI (n = 88)Gender (male/female)47/3551/370.934Age (years)56.54 ± 8.2558.00 ± 8.850.290BMI (kg/m2)24.88 ± 3.2324.68 ± 2.800.659CRP (mg/L)22.44 ± 3.9525.97 ± 4.01< 0.001PCT (ng/mL)5.50 ± 1.817.02 ± 1.86< 0.001CysC (mg/L)1.24 ± 0.301.40 ± 0.27< 0.001WBC (109/L)10.83 ± 4.9713.77 ± 4.11< 0.001APACHE II score19.88 ± 4.3726.14 ± 4.25< 0.001SOFA score9.64 ± 2.0612.51 ± 1.99< 0.001Hypertension (n/%)27/32.9329/32.950.997CHD (n/%)25/30.4919/21.590.188Diabetes (n/%)33/40.2442/47.730.329Abbreviation: ALI, acute lung injury; BMI, body mass index; CRP, C-reactive protein; PCT, procalcitonin; CysC, Cystatin C; PLT, Platelet; WBC, white blood cells; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; CHD, Coronary heart disease Table 2Grouping and clinical data comparison of sepsis patientsIndicatorsSepsis group (n = 170)P valueNon-ALI (n = 82)ALI (n = 88)Gender (male/female)47/3551/370.934Age (years)56.54 ± 8.2558.00 ± 8.850.290BMI (kg/m2)24.88 ± 3.2324.68 ± 2.800.659CRP (mg/L)22.44 ± 3.9525.97 ± 4.01< 0.001PCT (ng/mL)5.50 ± 1.817.02 ± 1.86< 0.001CysC (mg/L)1.24 ± 0.301.40 ± 0.27< 0.001WBC (109/L)10.83 ± 4.9713.77 ± 4.11< 0.001APACHE II score19.88 ± 4.3726.14 ± 4.25< 0.001SOFA score9.64 ± 2.0612.51 ± 1.99< 0.001Hypertension (n/%)27/32.9329/32.950.997CHD (n/%)25/30.4919/21.590.188Diabetes (n/%)33/40.2442/47.730.329Abbreviation: ALI, acute lung injury; BMI, body mass index; CRP, C-reactive protein; PCT, procalcitonin; CysC, Cystatin C; PLT, Platelet; WBC, white blood cells; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; CHD, Coronary heart disease Grouping and clinical data comparison of sepsis patients Abbreviation: ALI, acute lung injury; BMI, body mass index; CRP, C-reactive protein; PCT, procalcitonin; CysC, Cystatin C; PLT, Platelet; WBC, white blood cells; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; CHD, Coronary heart disease LINC00052 and miR-106b-5p in serum samples RT-qPCR analysis indicated that serum levels of LINC00052 were significantly lower in patients with sepsis compared to healthy controls (Fig. 1A). In contrast, miR-106b-5p expression was markedly upregulated in the sepsis group (Fig. 1B). Fig. 1Serum expression of LINC00052 and miR-106b-5p. Compared with the healthy group, patients in the sepsis group exhibited decreased expression of LINC00052 (A) and increased expression of miR-106b-5p in serum (B). ***P < 0.001 Serum expression of LINC00052 and miR-106b-5p. Compared with the healthy group, patients in the sepsis group exhibited decreased expression of LINC00052 (A) and increased expression of miR-106b-5p in serum (B). ***P < 0.001 Predictive potential of LINC00052 and miR-106b-5p for SA-ALI Serum LINC00052 was downregulated in the ALI group, while miR-106b-5p levels were elevated (Fig. 2A and B). This suggests that the occurrence of SA-ALI may be associated with their dysregulation. The AUC values for LINC00052, miR-106b-5p, and their combination were 0.849 (Cutoff value = 0.575, Sensitivity = 82.95%, Specificity = 78.05%), 0.765 (Cutoff value = 1.205, Sensitivity = 77.27%, Specificity = 69.51%), and 0.936 (Cutoff value = 0.319, Sensitivity = 98.84%, Specificity = 78.05%), respectively, suggesting that both indicators exhibit strong predictive potential for SA-ALI, with the combined model demonstrating superior diagnostic performance over biomarker alone (Fig. 2C). Fig. 2Expression and diagnostic value of LINC00052 and miR-106b-5p in ALI. Serum LINC00052 was down-regulated (A) and miR-106b-5p expression was up-regulated (B) in the ALI group compared with the non-ALI group. (C) LINC00052, miR-106b-5p and their combination in the diagnosis of SA-ALI. ***P < 0.001 Expression and diagnostic value of LINC00052 and miR-106b-5p in ALI. Serum LINC00052 was down-regulated (A) and miR-106b-5p expression was up-regulated (B) in the ALI group compared with the non-ALI group. (C) LINC00052, miR-106b-5p and their combination in the diagnosis of SA-ALI. ***P < 0.001 Additionally, Pearson correlation analysis indicated that LINC00052 levels were inversely correlated with clinical parameters including CRP (r=−0.762), PCT (r=−0.637), CysC (r=−0.681), and WBC (r=−0.687) (Fig. 3A and D). APACHE II score (r=−0.701) and SOFA score (r=−0.668) also showed negative correlation trend with LINC00052 expression (Fig. 3E and F). Meanwhile, Logistic regression analysis showed that LINC00052, miR-106b-5p, and the above indicators were confirmed as risk factors for SA-ALI (Table 3). Fig. 3Correlation analysis between LINC00052 and patient clinical parameters. LINC00052 expression showed an inverse trend with CRP (A), PCT (B), CysC (C), WBC (D), APACHE II (E), and SOFA scores (F). P < 0.001 Correlation analysis between LINC00052 and patient clinical parameters. LINC00052 expression showed an inverse trend with CRP (A), PCT (B), CysC (C), WBC (D), APACHE II (E), and SOFA scores (F). P < 0.001 Table 3Binary logistic regression analysis for SA-ALIIndicatorsP valueOR95% CILowerUpperLINC00052< 0.0010.1090.0340.344miR-106b-5p0.0170.2500.0800.777CRP< 0.0010.1000.0280.351PCT0.0010.1040.0290.379CysC0.0100.1950.0560.677WBC0.0360.2820.0870.919APACHE II score0.0010.1510.0470.482SOFA score< 0.0010.0820.0210.317Abbreviation: SA-ALI, sepsis-associated acute lung injury; CRP, C-reactive protein; PCT, procalcitonin; CysC, Cystatin C; PLT, Platelet; WBC, white blood cells; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment Table 3Binary logistic regression analysis for SA-ALIIndicatorsP valueOR95% CILowerUpperLINC00052< 0.0010.1090.0340.344miR-106b-5p0.0170.2500.0800.777CRP< 0.0010.1000.0280.351PCT0.0010.1040.0290.379CysC0.0100.1950.0560.677WBC0.0360.2820.0870.919APACHE II score0.0010.1510.0470.482SOFA score< 0.0010.0820.0210.317Abbreviation: SA-ALI, sepsis-associated acute lung injury; CRP, C-reactive protein; PCT, procalcitonin; CysC, Cystatin C; PLT, Platelet; WBC, white blood cells; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment Binary logistic regression analysis for SA-ALI Abbreviation: SA-ALI, sepsis-associated acute lung injury; CRP, C-reactive protein; PCT, procalcitonin; CysC, Cystatin C; PLT, Platelet; WBC, white blood cells; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment The targeting relationship between LINC00052 and miR-106b-5p Bioinformatics analysis predicted binding sites between LINC00052 and miR-106b-5p, as illustrated in Fig. 4A. The luciferase activity in the MUT-LINC00052 group remained unaffected by the dysregulation of miR-106b-5p, whereas it was significantly suppressed in the WT-LINC00052 group by the miR-106b-5p mimic (Fig. 4B). In line with the observations from serum samples, RT-qPCR analysis of an LPS-induced cell model further confirmed that LINC00052 expression was downregulated, while miR-106b-5p expression was markedly upregulated. Meanwhile, transfection with overexpression of LINC00052 restored the downregulation of LINC00052 caused by LPS (Fig. 4C). Transfection of ov-LINC00052 downregulated the miR-106b-5p level in A549 cells, but this effect was counteracted after transfection with miR-106b-5p mimic (Fig. 4D). Fig. 4miR-106b-5p is the target of LINC00052. (A) There were complementary sites between them. (B) The relationship was verified by luciferase activity assay. (C-D) Expression of LINC00052 and miR-106b-5p in A549 cells after LPS induction and overexpression of LINC00052 and miR-106b-5p transfection. ***P < 0.001 vs. control; ##P < 0.01 vs. LPS; &&P < 0.01 vs. LPS + ov-LINC00052 miR-106b-5p is the target of LINC00052. (A) There were complementary sites between them. (B) The relationship was verified by luciferase activity assay. (C-D) Expression of LINC00052 and miR-106b-5p in A549 cells after LPS induction and overexpression of LINC00052 and miR-106b-5p transfection. ***P < 0.001 vs. control; ##P < 0.01 vs. LPS; &&P < 0.01 vs. LPS + ov-LINC00052 Effect of LINC00052 and miR-106b-5p on inflammation and apoptosis of LPS-induced A549 cells After LPS exposure, the proliferation ability of A549 cells was suppressed, while the apoptosis rate was significantly increased. Up-regulation of LINC00052 restored cell viability and reduced cell apoptosis, while overexpression of miR-106b-5p partially reversed the effects of LINC00052 (Fig. 5A and B). Additionally, compared to the control group, the LPS group exhibited elevated concentrations of TNF-α and IL-1β, while LINC00052 mediated a reduction in inflammatory responses in A549 cells. Co-transfection with high levels of LINC00052 and miR-106b-5p restored inflammatory levels in the cells (Fig. 5C). Western Blot analysis demonstrated that the apoptotic factor Bcl-2 was markedly decreased, while the Bax and Caspase-3 protein expression was significantly increased after LPS stimulation. After transfection of ov-LINC00052 in cells, Bcl-2 level was up-regulated, while the Bax and Caspase-3 levels were down-regulated. However, the reversal effect of ov-LINC00052 on LPS-induced apoptosis was offset by miR-106b-5p mimic (Fig. 5D). Fig. 5Regulation of LINC00052 and miR-106b-5p on the biological function of A549 cells. Overexpression of LINC00052 affected LPS-induced cell viability (A), increased apoptosis (B), and aggravated inflammation (C), while miR-106b-5p mimic partially abolished these effects. (D) Effect of cells transfected with ov-LINC00052 and miR-106b-5p mimic on apoptotic factors after LPS exposure. **P < 0.01, ***P < 0.001 vs. control; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. LPS; &P < 0.05, &&P < 0.01, &&&P < 0.001 vs. LPS + ov-LINC00052 Regulation of LINC00052 and miR-106b-5p on the biological function of A549 cells. Overexpression of LINC00052 affected LPS-induced cell viability (A), increased apoptosis (B), and aggravated inflammation (C), while miR-106b-5p mimic partially abolished these effects. (D) Effect of cells transfected with ov-LINC00052 and miR-106b-5p mimic on apoptotic factors after LPS exposure. **P < 0.01, ***P < 0.001 vs. control; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. LPS; &P < 0.05, &&P < 0.01, &&&P < 0.001 vs. LPS + ov-LINC00052 Discussion In current clinical practice, the assessment of sepsis-related complications is heavily reliant on a combination of imaging studies, clinical scoring systems, and machine learning-based predictive models [20]. However, these methods often lack sensitivity for early or subtle changes. As molecular biomarkers gain increasing prominence, indicators such as ncRNAs and specific proteins are anticipated to substantially enhance the accuracy of patient diagnosis and the effectiveness of risk stratification [21]. Identifying the predictive and risk factors related to sepsis is conducive to facilitating timely intervention for patients and improving their prognosis, which may guide personalized nursing care and early risk monitoring for sepsis patients. We observed that the LINC00052 expression was strongly diminished in the serum of sepsis patients compared to healthy controls, whereas miR-106b-5p expression was markedly elevated. Based on whether sepsis patients were complicated by ALI or not, we further divided the patients into groups and recognized that the downregulation of LINC00052 and upregulation of miR-106b-5p were obviously more pronounced in ALI. The above implies that LINC00052 may exert a protective role in the pathological process of sepsis. Previous studies have reported that LINC00052 is frequently silenced in pancreatic cancer, and its high expression has been shown to significantly inhibit tumor growth [22]. In addition, silencing LINC00052 was considered as a potential target for breast cancer diagnosis [23]. Meanwhile, miR-106b-5p may be an indicator of pro-inflammatory and lung injury in sepsis. Wu et al. proposed that miR-106b-5p was predicted to be a target of lncRNA HOXA-AS2 and was positively expressed in sepsis-induced acute kidney injury [24]. These are consistent with the trend of our quantitative detection. Furthermore, LINC00052 levels inversely correlated with clinical parameters CRP, PCT, CysC, WBC, APACHE II and SOFA scores, reflecting its expression levels’ close association with SA-ALI severity. ROC curve and Logistic regression analysis revealed the great potential of LINC00052 and miR-106b-5p in the prediction of SA-ALI. These findings indicate that measuring the levels of LINC00052 and miR-106b-5p may be clinically useful in evaluating the risk of SA-ALI, highlighting their potential as non-invasive biomarkers. In clinical practice, the monitoring of LINC00052 and miR-106b-5p improves the early warning of SA-ALI, optimizes respiratory support nursing, and improves the efficiency of monitoring and management. The pathophysiology of ALI involves inflammatory damage to human lung epithelial cells, contributing significantly to disease progression [25]. We constructed in vitro ALI models by using A549 cells exposed to LPS. Bioinformatics analysis first predicted the binding sites between LINC00052 and miR-106b-5p and then verified their targeting relationship by luciferase reporter assay. LINC00052 was downregulated, whereas miR-106b-5p was upregulated in LPS-stimulated cells. This inverse expression pattern supports the hypothesis that LINC00052 may function as a suppressor of miR-106b-5p. In the report by et al., upregulation of miR-106b-5p was associated with microglial activation and inflammation in epilepsy [26]. Zheng and colleagues demonstrated that the highly expressed circ-DROSHA mitigates damage to temporal lobe epileptic cells by mediating miR-106b-5p [27]. Our data stated that enhanced LINC00052 restored LPS-induced inhibition of A549 cell proliferation, suppressed cellular inflammatory response and apoptosis, and thus reduced cell damage. Co-transfection of miR-106b-5p mimics abolished the protective effect of LINC00052. This implies that the LINC00052/miR-106b-5p axis is involved in the regulation of apoptosis and inflammation in SA-ALI. Restoring LINC00052 through the sponge and inhibiting miR-106b-5p may become a new strategy for SA-ALI. This study still has some limitations that should be acknowledged. Firstly, our investigation primarily relied on in vitro models and a relatively small clinical cohort. Further in vivo assays and larger-scale clinical validations are necessary to further confirm the therapeutic potential and diagnostic value of the LINC00052/miR-106b-5p axis. Secondly, although the specific downstream targets of miR-106b-5p require further validation, existing literature suggests that it may mediate inflammatory processes by regulating the JAK1/STAT3 signaling pathway and key targets such as GAB1 [28, 29]. Furthermore, the mediating effect of miR-106b-5p on specific targets (IRF1, HPGD and STAT3) has been widely characterized in a variety of malignancies [30–32]. However, the downstream targets of miR-106b-5p in SA-ALI have yet to be fully defined in the present study, highlighting the need for continued research in this area. Conclusions In conclusion, our findings elucidate the diagnostic and therapeutic potential of the LINC00052/miR-106b-5p axis in SA-ALI, opening new avenues for understanding the molecular mechanisms of SA-ALI and the refined care of patients with sepsis.